Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 24 studies | 30% ± 11% | |
| endothelial cell of lymphatic vessel | 12 studies | 24% ± 8% | |
| pericyte | 10 studies | 23% ± 7% | |
| endothelial cell of vascular tree | 10 studies | 34% ± 13% | |
| capillary endothelial cell | 8 studies | 23% ± 5% | |
| endothelial cell of artery | 8 studies | 29% ± 11% | |
| vein endothelial cell | 8 studies | 24% ± 9% | |
| fibroblast | 7 studies | 23% ± 5% | |
| smooth muscle cell | 6 studies | 19% ± 4% | |
| pro-B cell | 5 studies | 55% ± 17% | |
| hematopoietic stem cell | 4 studies | 24% ± 5% | |
| luminal cell of prostate epithelium | 4 studies | 25% ± 5% | |
| glomerular endothelial cell | 3 studies | 32% ± 3% | |
| connective tissue cell | 3 studies | 19% ± 4% |
Insufficient scRNA-seq data for expression of SOCS2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 7576.76 | 244 / 245 | 100% | 58.88 | 501 / 502 |
| adrenal gland | 99% | 2128.13 | 256 / 258 | 96% | 14.52 | 221 / 230 |
| thymus | 100% | 3065.02 | 652 / 653 | 89% | 9.71 | 539 / 605 |
| lung | 100% | 5044.45 | 578 / 578 | 86% | 12.50 | 993 / 1155 |
| intestine | 100% | 2525.16 | 965 / 966 | 76% | 5.01 | 401 / 527 |
| stomach | 99% | 2117.35 | 356 / 359 | 75% | 5.65 | 215 / 286 |
| uterus | 100% | 7335.06 | 170 / 170 | 74% | 11.28 | 340 / 459 |
| bladder | 100% | 2720.76 | 21 / 21 | 73% | 8.99 | 369 / 504 |
| kidney | 100% | 2231.18 | 89 / 89 | 70% | 7.54 | 633 / 901 |
| breast | 100% | 6176.90 | 459 / 459 | 69% | 10.18 | 769 / 1118 |
| esophagus | 90% | 1188.82 | 1297 / 1445 | 72% | 6.03 | 131 / 183 |
| pancreas | 56% | 471.71 | 183 / 328 | 90% | 7.73 | 161 / 178 |
| skin | 67% | 777.54 | 1206 / 1809 | 71% | 8.12 | 337 / 472 |
| liver | 63% | 1529.85 | 143 / 226 | 65% | 6.78 | 262 / 406 |
| ovary | 93% | 1596.71 | 167 / 180 | 12% | 0.86 | 51 / 430 |
| adipose | 100% | 4519.93 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 11.19 | 1 / 1 |
| brain | 24% | 178.95 | 631 / 2642 | 76% | 15.35 | 533 / 705 |
| blood vessel | 93% | 1909.07 | 1238 / 1335 | 0% | 0 | 0 / 0 |
| heart | 92% | 1379.53 | 794 / 861 | 0% | 0 | 0 / 0 |
| spleen | 85% | 682.04 | 206 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 60% | 5.69 | 27 / 45 |
| peripheral blood | 28% | 288.52 | 259 / 929 | 0% | 0 | 0 / 0 |
| muscle | 23% | 231.19 | 188 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 23% | 1.91 | 18 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 21% | 1.14 | 6 / 29 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0009966 | Biological process | regulation of signal transduction |
| GO_0032355 | Biological process | response to estradiol |
| GO_0016567 | Biological process | protein ubiquitination |
| GO_0001558 | Biological process | regulation of cell growth |
| GO_0046426 | Biological process | negative regulation of receptor signaling pathway via JAK-STAT |
| GO_0060396 | Biological process | growth hormone receptor signaling pathway |
| GO_0032870 | Biological process | cellular response to hormone stimulus |
| GO_0046854 | Biological process | phosphatidylinositol phosphate biosynthetic process |
| GO_0060749 | Biological process | mammary gland alveolus development |
| GO_0040015 | Biological process | negative regulation of multicellular organism growth |
| GO_0035556 | Biological process | intracellular signal transduction |
| GO_0043066 | Biological process | negative regulation of apoptotic process |
| GO_0007595 | Biological process | lactation |
| GO_0045666 | Biological process | positive regulation of neuron differentiation |
| GO_0007259 | Biological process | cell surface receptor signaling pathway via JAK-STAT |
| GO_0005942 | Cellular component | phosphatidylinositol 3-kinase complex |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005159 | Molecular function | insulin-like growth factor receptor binding |
| GO_0046935 | Molecular function | 1-phosphatidylinositol-3-kinase regulator activity |
| GO_0005131 | Molecular function | growth hormone receptor binding |
| GO_0008269 | Molecular function | JAK pathway signal transduction adaptor activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | SOCS2 |
| Protein name | Suppressor of cytokine signaling 2 (SOCS-2) (Cytokine-inducible SH2 protein 2) (CIS-2) (STAT-induced STAT inhibitor 2) (SSI-2) Suppressor of cytokine signaling 2 |
| Synonyms | SSI2 STATI2 CIS2 |
| Description | FUNCTION: SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. SOCS2 appears to be a negative regulator in the growth hormone/IGF1 signaling pathway. Probable substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. |
| Accessions | B5BU82 ENST00000551883.1 ENST00000622746.4 ENST00000548091.5 ENST00000548537.1 ENST00000549206.5 S4R3W1 ENST00000536696.6 ENST00000549887.1 ENST00000549122.5 F8VU91 S4R3Z4 ENST00000549510.1 O14508 ENST00000551556.2 F8VRV3 ENST00000340600.6 F8VS53 |